Financial Snapshot

Revenue
$191.4M
TTM
Gross Margin
74.23%
TTM
Net Earnings
-$56.54M
TTM
Current Assets
Q2 2024
Current Liabilities
Q2 2024
Current Ratio
763.4%
Q2 2024
Total Assets
Q2 2024
Total Liabilities
Q2 2024
Book Value
$154.7M
Q2 2024
Cash
Q2 2024
P/E
-19.76
Sep 16, 2024 EST
Free Cash Flow
-$36.08M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $177.1M $138.6M $101.5M $75.23M $63.35M $34.56M $14.26M
YoY Change 27.77% 36.62% 34.89% 18.74% 83.33% 142.34%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $177.1M $138.6M $101.5M $75.23M $63.35M $34.56M $14.26M
Cost Of Revenue $50.05M $37.88M $25.45M $21.29M $15.93M $10.87M $5.130M
Gross Profit $127.1M $100.8M $76.03M $53.94M $47.43M $23.68M $9.130M
Gross Profit Margin 71.75% 72.68% 74.92% 71.7% 74.86% 68.53% 64.03%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017
Selling, General & Admin $145.0M $116.3M $96.39M $75.52M $63.22M $34.82M $20.26M
YoY Change 24.69% 20.68% 27.62% 19.46% 81.56% 71.87%
% of Gross Profit 114.12% 115.44% 126.78% 140.03% 133.3% 147.03% 221.91%
Research & Development $41.32M $36.45M $27.11M $21.27M $12.27M $10.26M $7.240M
YoY Change 13.37% 34.45% 27.45% 73.33% 19.63% 41.69%
% of Gross Profit 32.52% 36.17% 35.66% 39.44% 25.88% 43.31% 79.3%
Depreciation & Amortization $2.696M $2.127M $1.032M $789.0K $712.0K $517.0K $130.0K
YoY Change 26.75% 106.1% 30.8% 10.81% 37.72% 297.69%
% of Gross Profit 2.12% 2.11% 1.36% 1.46% 1.5% 2.18% 1.42%
Operating Expenses $186.4M $152.8M $123.5M $96.80M $75.49M $45.08M $27.50M
YoY Change 21.99% 23.7% 27.59% 28.22% 67.47% 63.92%
Operating Profit -$59.27M -$52.00M -$47.47M -$42.86M -$28.07M -$21.40M -$18.37M
YoY Change 13.97% 9.56% 10.75% 52.71% 31.18% 16.47%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017
Interest Expense $6.871M $5.098M $2.518M $4.411M $4.952M $4.361M -$3.910M
YoY Change 34.78% 102.46% -42.92% -10.92% 13.55% -211.53%
% of Operating Profit
Other Income/Expense, Net $442.0K -$190.0K -$23.00K -$80.00K -$21.05M -$12.06M $2.930M
YoY Change -332.63% 726.09% -71.25% -99.62% 74.53% -511.71%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017
Pretax Income -$55.74M -$55.01M -$49.81M -$47.37M -$52.42M -$37.63M -$19.36M
YoY Change 1.33% 10.44% 5.16% -9.63% 39.29% 94.37%
Income Tax $43.00K $29.00K $20.00K $11.00K $8.000K $14.00K $0.00
% Of Pretax Income
Net Earnings -$55.74M -$55.01M -$49.81M -$47.37M -$52.42M -$37.63M -$19.36M
YoY Change 1.33% 10.44% 5.16% -9.63% 39.29% 94.36%
Net Earnings / Revenue -31.47% -39.68% -49.09% -62.96% -82.73% -108.89% -135.76%
Basic Earnings Per Share -$1.44 -$1.54 -$1.44 -$1.44
Diluted Earnings Per Share -$1.44 -$1.54 -$1.438M -$1.437M -$2.283M -$1.245M -$640.4K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017
Cash & Short-Term Investments $181.5M $213.7M $110.2M $147.5M $90.70M $25.00M $33.30M
YoY Change -15.07% 93.84% -25.27% 62.62% 262.8% -24.92%
Cash & Equivalents $20.21M $55.36M $110.2M $69.50M $39.20M $25.00M $33.30M
Short-Term Investments $161.3M $158.3M $0.00 $78.00M $51.50M $0.00
Other Short-Term Assets $5.912M $3.924M $3.412M $6.800M $2.900M $1.400M $300.0K
YoY Change 50.66% 15.01% -49.82% 134.48% 107.14% 366.67%
Inventory $29.88M $19.29M $17.85M $10.00M $10.30M $5.700M $3.200M
Prepaid Expenses
Receivables $23.57M $18.01M $11.83M $9.100M $8.600M $6.400M $5.200M
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Total Short-Term Assets $240.8M $254.9M $143.3M $173.3M $112.5M $38.50M $42.10M
YoY Change -5.52% 77.84% -17.3% 54.04% 192.21% -8.55%
Property, Plant & Equipment $14.60M $14.45M $12.92M $5.600M $6.100M $2.900M $500.0K
YoY Change 1.04% 11.9% 130.64% -8.2% 110.34% 480.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $9.456M $0.00 $18.20M $0.00
YoY Change -100.0%
Other Assets $415.0K $334.0K $383.0K $300.0K $600.0K $1.300M $500.0K
YoY Change 24.25% -12.79% 27.67% -50.0% -53.85% 160.0%
Total Long-Term Assets $24.47M $14.79M $13.30M $6.000M $24.90M $4.200M $1.000M
YoY Change 65.51% 11.19% 121.65% -75.9% 492.86% 320.0%
Total Assets $265.3M $269.7M $156.6M $179.3M $137.4M $42.70M $43.10M
YoY Change
Accounts Payable $5.676M $2.523M $2.379M $2.600M $1.900M $1.300M $1.500M
YoY Change 124.97% 6.05% -8.5% 36.84% 46.15% -13.33%
Accrued Expenses $24.46M $21.71M $19.65M $16.80M $15.00M $9.400M $3.100M
YoY Change 12.68% 10.52% 16.93% 12.0% 59.57% 203.23%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $3.905M $0.00 $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $30.28M $24.49M $26.09M $19.60M $16.90M $10.70M $4.700M
YoY Change 23.66% -6.13% 33.09% 15.98% 57.94% 127.66%
Long-Term Debt $75.63M $74.60M $44.79M $48.50M $44.90M $44.20M $27.60M
YoY Change 1.38% 66.56% -7.66% 8.02% 1.58% 60.14%
Other Long-Term Liabilities $8.249M $6.726M $6.513M $3.700M $3.700M $17.20M $4.200M
YoY Change 22.64% 3.27% 76.03% 0.0% -78.49% 309.52%
Total Long-Term Liabilities $83.88M $81.32M $51.30M $52.20M $48.60M $61.40M $31.80M
YoY Change 3.14% 58.53% -1.73% 7.41% -20.85% 93.08%
Total Liabilities $114.2M $105.8M $77.39M $71.80M $65.50M $72.10M $36.40M
YoY Change 7.89% 36.73% 7.78% 9.62% -9.15% 98.08%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017
Basic Shares Outstanding 38.80M 35.78M 34.64M 32.97M
Diluted Shares Outstanding 38.80M 35.78M 34.64M 32.97M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $1.117 Billion

About Silk Road Medical Inc

Silk Road Medical, Inc. engages in the development and manufacturing of medical devices to treat neurovascular diseases. The company is headquartered in Sunnyvale, California and currently employs 474 full-time employees. The company went IPO on 2019-04-04. The firm has developed an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. Its product portfolio consists of five single-use components: ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent System, ENHANCE Transcarotid Peripheral Access Kit, ENROUTE 0.014'' Guidewire and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter. The company manufactures ENROUTE NPS and ENROUTE NPS PLUS, or its ENROUTE NPS products, at its facilities in Sunnyvale, California and Plymouth, Minnesota. These facilities provide an aggregate of over 35,000 square feet of space for its production and distribution operations.

Industry: Surgical & Medical Instruments & Apparatus Peers: ATRION CORP Avanos Medical Inc Embecta Corp Figs Inc MERIDIAN BIOSCIENCE INC MERIT MEDICAL SYSTEMS INC Neogen Corp OrthoPediatrics Corp STAAR Surgical Co